The Annals Visit the NEW pharmaCE.com
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 17 February 2010, www.theannals.com, DOI 10.1345/aph.1M210.
 The Annals of Pharmacotherapy: Vol. 44, No. 3, pp. 538-545. DOI 10.1345/aph.1M210
© 2010 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dunican, K. C
Right arrow Articles by Desilets, A. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunican, K. C
Right arrow Articles by Desilets, A. R

OBESITY

The Role of Pramlintide for Weight Loss

Kaelen C Dunican, PharmD

Assistant Professor of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences-Worcester/Manchester, Worcester, MA

Nicole M Adams, PharmD

Staff Pharmacist, Rite Aid Pharmacy, Milford, CT

Alicia R Desilets, PharmD

Assistant Professor of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences-Worcester/Manchester

Reprints: Dr. Dunican, 19 Foster St., Worcester, MA 01608, fax 508/756-8715, Kaelen.Dunican{at}mcphs.edu

OBJECTIVE: To evaluate the weight-loss effects of pramlintide.

DATA SOURCES: A literature search was conducted in MEDLINE (1950-October week 4, 2009), International Pharmaceutical Abstracts (1970-October 2009), and Evidence Based Medicine Database (1991-2009 week 44) to identify relevant publications. Key words searched included pramlintide, weight loss, obesity, and overweight. Additional data sources were obtained through a bibliographic review of selected articles.

STUDY SELECTION/DATA EXTRACTION: All studies conducted on humans and published in English that examined the effects of pramlintide on body weight as a primary or secondary endpoint were selected for analysis.

DATA SYNTHESIS: Pramlintide is a human amylin analog approved by the Food and Drug Administration for use in conjunction with insulin therapy in patients with type 1 or 2 diabetes. In addition to its glucoregulatory actions, pramlintide has been shown to increase satiety and, therefore, decrease caloric intake via a central mechanism. Several studies show that this translates into statistically significant weight loss in overweight or obese patients with type 1 or 2 diabetes; patients with type 1 diabetes lost up to 1.7 kg over 1 year with pramlintide 60 µg 3 times daily, while patients with type 2 diabetes experienced a placebo-subtracted weight loss of up to 3.7 kg after 16 weeks of pramlintide 120-240 µg administered 3 times daily. Preliminary trials assessing the use of pramlintide for weight loss in obese patients without diabetes have demonstrated weight loss of up to 8 kg after 1 year. In all studies, the drug was generally well tolerated, with nausea being the most commonly reported adverse effect.

CONCLUSIONS: Based on preliminary evidence, pramlintide facilitates modest weight loss in obese or overweight patients with and without diabetes. However, current trials were limited by inconsistent study design, dosing, and patient population.

Key Words: obesity, overweight, pramlintide, weight loss

Published Online, February 17, 2010. www.theannals.com, DOI 10.1345/aph.1M210




homecopy help contact us subscription past issues search current issue
Copyright © 2010 by Harvey Whitney Books Company.